Press Releases

Azur Pharma acquired product rights to Gastrocrom

acquired product rights to Gastrocrom
January 2006

Azur Pharma Limited (“Azur Pharma”) today announced that it has acquired the U.S. rights to Gastrocrom® (cromolyn sodium, usp Oral Concentrate) from UCB Pharma, Inc (“UCB”).  Gastrocrom® is indicated in the management of patients suffering from mastocytosis, a rare disorder characterized by an abnormal accumulation of mast cells in various organ systems.  Annual sales of Gastrocrom® amount to approximately US$5 million.

“I am pleased to announce our first product acquisition, Gastrocrom®, a mature and stable prescription product indicated for a rare and often chronic disorder.  This acquisition is an important first step as we seek to execute on our mission of creating a U.S. pharmaceutical business focused on developing and marketing products in specialist therapeutic areas.” commented Mr. Seamus Mulligan, Azur Pharma’s Chairman and Chief Executive Officer.